EFFECT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND COMBINATION ANTIRETROVIRAL THERAPY ON TELOMERE LENGTH
Abstract
Introduction: Due to combination antiretroviral therapy (cART), human immunodeficiency virus (HIV) infection has been transformed into a chronic disease. Despite effective therapy, the virus continues to replicate in the body. Chronic inflammation caused by the constant presence of the virus and cumulative toxicity caused by the therapy lead to changes in the body, potentially associated with an accelerated aging process.
Objective: The objective of this paper was to review and analyze the most common mechanisms by which HIV infection and cART can affect telomere length.
Material and Methods: This review used targeted searches of the MEDLINE and PubMed bibliographic databases using the keywords "telomeres", "telomere length", "telomere attrition", "aging" and "cellular senescence" in combination with the words "HIV", " HIV infection", "antiretroviral", "cART" and "HAART".
Results: HIV-infection-related parameters affecting telomere shortening are the presence of viral Tat protein in the cell, oxidative stress, comorbidities and aberrant methylation. Drugs within cART that stand out as important for telomere shortening are efavirenz, tenofovir and dolutegravir.
Conclusion: Tat and Vpr proteins, oxidative stress, DNA methylation, efavirenz administration, tenofovir administration, and dolutegravir administration can significantly affect telomere shortening in HIV-infected patients.
References
1. Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the Highly Active Antiretroviral Therapy Era, JAIDS. 2006 Sep; 43(1):27-34.
2. Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, et al. A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. Infect Dis Ther. 2018 Jun; 7(2):183-195.
3. Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2012 Mar; 54(5):724-32.
4. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997 Nov; 94:13193-7.
5. Althoff KN, Smit M, Reiss P, Justice AC. HIV and ageing: improving quantity and quality of life. Curr Opin HIV AIDS. 2016 Sep; 11(5):527-536.
6. De Francesco D, Wit FW, Bürkle A, Oehlke S, Kootstra NA, Winston A et al. Do people living with HIV experience greater age advancement than their HIV-negative counterparts? AIDS. 2019 Feb; 33(2):259-268.
7. Nasi M, De Biasi S, Gibelini L, Bianchini E, Pecorini S, Bacca V, et al. Ageing and inflammation in patients with HIV infection. Clinical & Experimental Immunology. 2016 Jan; 187(1):44-52.
8. Lagathu C, Cossarizza A, Béréziat V, Nasi M, Capeau J, Pinti Marcello. Basic science and pathogenesis of ageing with HIV. AIDS. 2017 Jun; 31:105-119.
9. Turner KJ, Vasu V, Griffin DK. Telomere Biology and Human Phenotype. Cells. 2019 Jan; 19;8(1):73.
10. Armstrong CA, Tomita K. Fundamental mechanisms of telomerase action in yeasts and mammals: Understanding telomeres and telomerase in cancer cells. Open Biology. 2017 Mar; 7:160338.
11. Zanet DL, Thorne A, Singer J, Maan EJ, Sattha B, Le Campion A, et al. Association between short leukocyte telomere length and HIV infection in a cohort study: No evidence of a relationship with antiretroviral therapy. Clin Infect Dis. 2014 May; 58(9):1322-32.
12. Dragovic G, Andjic M, Toljic B, Jevtovic Dj, Lukic R, de Luka S, et al. Correlation between metabolic syndrome and relative telomere length shortening in HIV/AIDS patients on combined antiretroviral therapy. Experimental Gerontology. 2021 May; 147:111269.
13. World Health Organization. Consolidate guidelines on the use of antiretroviral drugs for treating andpreventing HIV infection [citirano 12.07.2023. godine]. Available online: https://www.who.int/data/gho/data/themes/hiv-aids.
14. Alejos B, Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Schwimmer C, et al. Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial. HIV Med. 2019 Nov; 20(10):691-698.
15. National Library of Medicine. Acquired Immune Deficiency Syndrome CD4+ Count [citirano 12.07.2023. godine]. Available online: https://www.ncbi.nlm.nih.gov/books/NBK513289/.
16. Prasad K. C-reactive protein increases oxygen radical generation by neutrophils. J Cardiovasc Pharmacol Ther. 2004 Sep; 9(3):203-9.
17. Wong JY, De Vivo I, Lin X, Fang SC, Christiani DC. The relationship between inflammatory biomarkers and telomere length in an occupational prospective cohort study. PLoS One. 2014 Jan 27;9(1):e87348.
18. Gonzalez-Serna A, Ajaykumar A, Gadawski I, Muñoz-Fernández MA, Hayashi K, Harrigan PR, et al. Rapid Decrease in Peripheral Blood Mononucleated Cell Telomere Length After HIV Seroconversion, but Not HCV Seroconversion. J Acquir Immune Defic Syndr. 2017 Sep; 76(1):e29-e32.
19. Ajasin D, Eugenin EA. HIV-1 Tat: Role in Bystander Toxicity. Front Cell Infect Microbiol. 2020 Feb; 10:61.
20. Rice AP. The HIV-1 Tat Protein: Mechanism of Action and Target for HIV-1 Cure Strategies. Curr Pharm Des. 2017;23(28):4098-4102.
21. Comandini A, Naro C, Adamo R, Akbar AN, Lanna A, Bonmassar E, et al. Molecular mechanisms involved in HIV-1-Tat mediated inhibition of telomerase activity in human CD4(+) T lymphocytes. Mol Immunol. 2013 Jun; 54(2):181-92.
22. Deshmane SL, Mukerjee R, Fan S, Del Valle L, Michiels C, Sweet T, et al. Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1alpha expression. J Biol Chem. 2009 Apr; 284(17):11364-73.
23. Li C, Zhou HM. The role of manganese superoxide dismutase in inflammation defense. Enzyme Res. 2011; 2011:387176.
24. Kogan M, Rappaport J. HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology. 2011 Apr; 8:25.
25. Wang X, Singh S, Jung HY, Yang G, Jun S, Sastry KJ, Park JI. HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3 ligase complex. J Biol Chem. 2013 May; 288(22):15474-80.
26. Deshmane SL, Mukerjee R, Fan S, Del Valle L, Michiels C, Sweet T, Rom I, Khalili K, Rappaport J, Amini S, Sawaya BE. Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1alpha expression. J Biol Chem. 2009 Apr; 284(17):11364-73.
27. Betteridge DJ. What is oxidative stress? Metabolism. 2000 Feb; 49(2 Suppl 1):3-8.
28. Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, Squadrito F, Altavilla D, Bitto A. Oxidative Stress: Harms and Benefits for Human Health. Oxid Med Cell Longev. 2017;2017:8416763.
29. Ivanov AV, Valuev-Elliston VT, Ivanova ON, Kochetkov SN, Starodubova ES, Bartosch B, et al. Oxidative Stress during HIV Infection: Mechanisms and Consequences. Oxid Med Cell Longev. 2016; 2016:8910396.
30. Barnes RP, Fouquerel E, Opresko PL. The impact of oxidative DNA damage and stress on telomere homeostasis. Mech Ageing Dev. 2019 Jan; 177:37-45.
31. Cadet J, Wagner JR. DNA base damage by reactive oxygen species, oxidizing agents, and UV radiation. Cold Spring Harb Perspect Biol. 2013 Feb; 5(2):a012559.
32. Sfeir A, Kosiyatrakul ST, Hockemeyer D, MacRae SL, Karlseder J, Schildkraut CL, de Lange T. Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication. Cell. 2009 Jul; 138(1):90-103.
33. Fleming AM, Burrows CJ. Formation and processing of DNA damage substrates for the hNEIL enzymes. Free Radic Biol Med. 2017 Jun; 107:35-52.
34. Rudd SG, Valerie NCK, Helleday T. Pathways controlling dNTP pools to maintain genome stability. DNA Repair (Amst). 2016 Aug; 44:193-204.
35. Aeby E, Ahmed W, Redon S, Simanis V, Lingner J. Peroxiredoxin 1 Protects Telomeres from Oxidative Damage and Preserves Telomeric DNA for Extension by Telomerase. Cell Rep. 2016 Dec; 17(12):3107-3114.
36. Qian W, Kumar N, Roginskaya V, Fouquerel E, Opresko PL, et al. Chemoptogenetic damage to mitochondria causes rapid telomere dysfunction. Proc Natl Acad Sci USA. 2019;116(37):18435-18444.
37. Ahmed S, Passos JF, Birket MJ, Beckmann T, Brings S, Peters H, et al. Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress. J Cell Sci. 2008 Apr; 121(7):1046-53.
38. Hsieh AYY, Kimmel E, Pick N, Sauvé L, Brophy J, Kakkar F et al. Inverse relationship between leukocyte telomere length attrition and blood mitochondrial DNA content loss over time. Aging. 2020 Jul; 12(15):15196-15221.
39. Bird, A. DNA methylation patterns and epigenetic memory. Genes. 2002; 16,6–21.
40. Rickabaugh TM, Baxter RM, Sehl M, Sinsheimer JS, Hultin PM, Hultin LE, et al. Acceleration of age-associated methylation patterns in HIV-1-infected adults. PLoS One. 2015 Mar; 10(3):e0119201.
41. Lagathu C, Cossarizza A, Béréziat V, Nasi M, Capeau J, Pinti M. Basic science and pathogenesis of ageing with HIV. AIDS. 2017 Jun, 31:105-119.
42. Johnson AA, Akman K, Calimport SR, Wuttke D, Stolzing A, de Magalhães JP. The role of DNA methylation in aging, rejuvenation, and age-related disease. Rejuvenation Res. 2012 Okt; 15(5):483-94.
43. Shu C, Jaffe AE, Sabunciyan S, Ji H, Astemborski J, Sun J, Bakulski KM, et al. Epigenome-wide association scan identifies methylation sites associated with HIV infection. Epigenomics. 2020 Nov; 12(21):1917-1927.
44. Zhang D, Wen X, Zhang L, Cui W. DNA methylation of human telomerase reverse transcriptase associated with leukocyte telomere length shortening in hyperhomocysteinemia-type hypertension in humans and in a rat model. Circ J. 2014 May; 78(8):1915-23.
45. Roomaney RA, van Wyk B, Pillay-van Wyk V. Aging with HIV: Increased Risk of HIV Comorbidities in Older Adults. Int J Environ Res Public Health. 2022 Feb;19(4):2359.
46. Lorenc A, Ananthavarathan P, Lorigan J, Jowata M, Brook G, Banarsee R. The prevalence of comorbidities among people living with HIV in Brent: a diverse London Borough. London J Prim Care (Abingdon). 2014; 6(4):84-90.
47. Pourcher V, Gourmelen J, Bureau I, Bouee S. Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France. PLoS One. 2020 Dec 17;15(12):e0243529.
48. Triant VA. Cardiovascular disease and HIV infection. Curr HIV/AIDS Rep. 2013 Sep; 10(3):199-206.
49. Brown TT, Cole SR, Kingsley LA, Palella FJ, Riddler SA, Visscher BR, Margoluck JB, Dobs AS: Antiretroviral Therapy and the prevalence and incidence of diabetes in a multicenter AIDS Cohort study. Arch Interm Med. 2005, 165: 1179-1184.
50. Feinstein MJ. HIV and Cardiovascular Disease: From Insights to Interventions. Top Antivir Med. 2021 Oct-Nov; 29(4):407-411.
51. Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and Weight Gain in Persons with HIV. Curr HIV/AIDS Rep. 2020 Apr;17(2):138-150.
52. Quin J. Diabetes and HIV. Clin Med (Lond). 2014 Dec; 14(6):667-9.
53. Kumar S, Samaras K. The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Front Endocrinol (Lausanne). 2018 Nov; 9:705.
54. Cheng F, Carroll L, Joglekar MV, Januszewski AS, Wong KK, Hardikar AA, et al. Diabetes, metabolic disease, and telomere length. Lancet Diabetes Endocrinol. 2021 Feb; 9(2):117-126.
55. Gielen M, Hageman GJ, Antoniou EE, Nordfjall K, Mangino M, Balasubramanyam M, et al. Body mass index is negatively associated with telomere length: a collaborative cross-sectional meta-analysis of 87 observational studies. Am J Clin Nutr. 2018 Sep; 108(3):453-475.
56. Zeng JB, Liu HB, Ping F, Li W, Li YX. Insulin treatment affects leukocyte telomere length in patients with type 2 diabetes: 6-year longitudinal study. J Diabetes Complications. 2019 May; 33(5):363-367.
57. Liu J, Ge Y, Wu S, Ma D, Xu W, Zhang Y, et al. Association between antidiabetic agents use and leukocyte telomere shortening rates in patients with type 2 diabetes. Aging (Albany NY). 2019 Jan; 11(2):741-755.
58. Hukezalie KR, Thumati NR, Côté HC, Wong JM. In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs. PLoS One. 2012 Nov; 7(11):e47505.
59. O'Callaghan NJ, Bull C, Fenech M. Elevated plasma magnesium and calcium may be associated with shorter telomeres in older South Australian women. J Nutr Health Aging. 2014; 18(2):131-6.
60. Maeda T, Oyama J, Higuchi Y, Koyanagi M, Sasaki M, Arima T, et al. The correlation between clinical laboratory data and telomeric status of male patients with metabolic disorders and no clinical history of vascular events. Aging Male. 2011 Jul; 14(1):21-6.
61. Babu H, Ambikan AT, Gabriel EE, Svensson AS, Palaniappan AN, Sundaraj V, et al. Systemic Inflammation and the Increased Risk of Inflamm-Aging and Age-Associated Diseases in People Living With HIV on Long Term Suppressive Antiretroviral Therapy. Front Immunol. 2019 Aug; 10:1965.
62. Surnar B, Shah AS, Park M, Kalathil AA, Kamran MZ, Ramirez Jaime R, et al. Brain-Accumulating Nanoparticles for Assisting Astrocytes to Reduce Human Immunodeficiency Virus and Drug Abuse-Induced Neuroinflammation and Oxidative Stress. ACS Nano. 2021 Aug; 15(10):15741-15753.
63. Brown LA, Jin J, Ferrell D, Sadic E, Obregon D, Smith AJ, et al. Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND). PLoS One. 2014 Apr; 9(4):e95500.
64. Benedicto AM, Fuster-Martínez I, Tosca J, Esplugues JV, Blas-García A, Apostolova N. NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved. Cells. 2021;10(7):1687.
65. Clifford W Fong. Efavirenz free radicals, oxidative stress and CNS toxicity in HIV infections and anti-cancer therapies: quantum mechanical study. Eigenenergy Adelaide. 2022.
66. Dong Q, Oh J, Yi JK, Kim RH, Shin K, Mitsuyasu R, et al. Efavirenz induces autophagy and aberrant differentiation in normal human keratinocytes. Int J Mol Med 31. 2013 Jun; 1305-1312.
67. Tutton S, Lieberman PM. A role for p53 in telomere protection. Mol Cell Oncol. 2016: Feb; 4(6):e1143078.
68. Leeansyah E, Cameron PU, Solomon A, Tennakoon S, Velayudham P, Gouillou M, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr; 207(7):1157-65.
69. Vivanti A, Soheili TS, Cuccuini W, Luce S, Mandelbrot L, Lechenadec J, et al. Comparing genotoxic signatures in cord blood cells from neonates exposed in utero to zidovudine or tenofovir. AIDS. 2015 Jul; 29(11):1319-24.
70. Hsiao CB, Bedi H, Gomez R, Khan A, Meciszewski T, Aalinkeel R, et al. Telomere Length Shortening in Microglia: Implication for Accelerated Senescence and Neurocognitive Deficits in HIV. Vaccines (Basel). 2021 Jul 1;9(7):721.